SARS-CoV-2 Infection and Transmission Inhibitor
Subhash Chandra1, 2, *, Sakshi2, Sarla Saklani2, Alka N Choudhary1, Kanishk Kala3
Identifiers and Pagination:Year: 2023
E-location ID: e266695872306070
Publisher ID: e266695872306070
Article History:Received Date: 28/02/2023
Revision Received Date: 23/04/2023
Acceptance Date: 21/05/2023
Electronic publication date: 11/07/2023
Collection year: 2023
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
As of December 2019, there has been an outbreak of severe respiratory syndrome coronavirus-2 (SARS-CoV-2) in China. Around 16% of patients developed acute respiratory distress syndrome, and 1%–2% died. There is no specific treatment reported. A pandemic related to Coronavirus is one of the most significant health crises in human history. In spite of a massive influx of cases, SARS-CoV-2 is still untreatable. Both old and novel virologic medicines were tested in order to develop a novel drug or vaccine. In advanced clinical trials in the US, favipiravir is currently approved for treating influenza infections in Japan, and it has been approved for treating SARS-CoV-2 or COVID-19 infections in Japan. Studies have shown that favipiravir can treat mild to moderate COVID-19 infections. The present review examines the role and use of favipiravir in the treatment of COVID-19. The purpose of this review is to provide evidence obtained from a variety of authentic sources. Current research is evaluating favipiravir for treating Coronavirus infections.